The next-generation oral antiandrogen product apalutamide (Erleada, Janssen), is approaching approval in Europe for use in nonmetastatic castration-resistant prostate cancer (nmCRPC). The product ...

Among prostate cancer patients with a luminal B subtype, the 5-year biochemical progression-free survival rate was 72% in the apalutamide group and 54% in the placebo group. Recurrent prostate cancer ...

Investigators expanded on previous results from the DEAR study, comparing darolutamide versus enzalutamide and apalutamide ...

A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrate-resistant prostate cancer and certain other immunologically cold tumors. Background: Androgen deprivation therapy (ADT) with ...

3-weekly docetaxel 75 mg/m2 vs 2-weekly docetaxel 50 mg/m2 in combination with darolutamide + ADT in patients with mHSPC: Subgroup analyses from the randomised phase 3 ARASAFE trial. This is an ASCO ...

SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits when apalutamide (Erleada) was added to salvage radiotherapy after radical ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants, investigators found no evidence of an increase in patients' ...

A diverticulitis concern led to a prostate cancer diagnosis that shifted a patient's mindset and highlighted the importance of hisloved ones. Bob Lane, a prostate cancer survivor on Erleada ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...